[1]CurrentPatentAssignee:UNIVERSITYSYSTEMOFOHIO-WO2005/44130,2005,A1Locationinpatent:Page/Pagecolumn28;2/2
[2]CurrentPatentAssignee:UNIVERSITYSYSTEMOFOHIO-US2009/111799,2009,A1Locationinpatent:Page/Pagecolumn18;20-21;sheet2
[3]Locationinpatent:schemeortableChiu,Hao-Chieh;Lee,Su-Lin;Kapuriya,Naval;Wang,Dasheng;Chen,Yi-Ru;Yu,Sung-Liang;Kulp,SamuelK.;Teng,Lee-Jene;Chen,Ching-Shih[BioorganicandMedicinalChemistry,2012,vol.20,#15,p.4653-4660]
[1]Chiu,Hao-Chieh;Lee,Su-Lin;Kapuriya,Naval;Wang,Dasheng;Chen,Yi-Ru;Yu,Sung-Liang;Kulp,SamuelK.;Teng,Lee-Jene;Chen,Ching-Shih[BioorganicandMedicinalChemistry,2012,vol.20,#15,p.4653-4660]
[2]Lee,Donghee;Lee,Yunmi;HyeShin,Son;MinChoi,Su;HyeonLee,Shin;Jeong,Seonghun;Jang,Soojin;Kee,Jung-Min[BioorganicChemistry,2023,vol.130]
[1]Chiu,Hao-Chieh;Lee,Su-Lin;Kapuriya,Naval;Wang,Dasheng;Chen,Yi-Ru;Yu,Sung-Liang;Kulp,SamuelK.;Teng,Lee-Jene;Chen,Ching-Shih[BioorganicandMedicinalChemistry,2012,vol.20,#15,p.4653-4660]
[2]Lee,Donghee;Lee,Yunmi;HyeShin,Son;MinChoi,Su;HyeonLee,Shin;Jeong,Seonghun;Jang,Soojin;Kee,Jung-Min[BioorganicChemistry,2023,vol.130]
[3]Lee,Donghee;Lee,Yunmi;HyeShin,Son;MinChoi,Su;HyeonLee,Shin;Jeong,Seonghun;Jang,Soojin;Kee,Jung-Min[BioorganicChemistry,2023,vol.130]
[1]BioorganicandMedicinalChemistry,2012,vol.20,p.4653-4660
[1]Chiu,Hao-Chieh;Lee,Su-Lin;Kapuriya,Naval;Wang,Dasheng;Chen,Yi-Ru;Yu,Sung-Liang;Kulp,SamuelK.;Teng,Lee-Jene;Chen,Ching-Shih[BioorganicandMedicinalChemistry,2012,vol.20,#15,p.4653-4660]
Title: Development of novel antibacterial agents against methicillin-resistant Staphylococcus aureus.
Journal: Bioorganic & medicinal chemistry 20120801
Title: Identification, in vitro activity and mode of action of phosphoinositide-dependent-1 kinase inhibitors as antifungal molecules.
Journal: ACS chemical biology 20110520
Title: YB-1 drives preneoplastic progression: Insight into opportunities for cancer prevention.
Journal: Oncotarget 20110501
Title: Suppression of Her2/neu expression through ILK inhibition is regulated by a pathway involving TWIST and YB-1.
Journal: Oncogene 20101202
Title: OSU-03012, a novel celecoxib derivative, induces cell swelling and shortens action potential duration in mouse ventricular cells.
Journal: Biomedical research (Tokyo, Japan) 20101201
Title: Exploring the molecular mechanisms of OSU-03012 on vascular smooth muscle cell proliferation.
Journal: Molecular and cellular biochemistry 20101101
Title: OSU-03012 sensitizes TIB-196 myeloma cells to imatinib mesylate via AMP-activated protein kinase and STAT3 pathways.
Journal: Leukemia research 20100601
Title: Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells.
Journal: European journal of cancer (Oxford, England : 1990) 20090601
Title: Nuclear detection of Y-box protein-1 (YB-1) closely associates with progesterone receptor negativity and is a strong adverse survival factor in human breast cancer.
Journal: BMC cancer 20090101
Title: Eradication of intracellular Francisella tularensis in THP-1 human macrophages with a novel autophagy inducing agent.
Journal: Journal of biomedical science 20090101
Title: OSU03012 activates Erk1/2 and Cdks leading to the accumulation of cells in the S-phase and apoptosis.
Journal: International journal of cancer 20081215
Title: Sensitivity to the non-COX inhibiting celecoxib derivative, OSU03012, is p21(WAF1/CIP1) dependent.
Journal: International journal of cancer 20081215
Title: OSU-03012, a novel celecoxib derivative, induces reactive oxygen species-related autophagy in hepatocellular carcinoma.
Journal: Cancer research 20081115
Title: Targeting endoplasmic reticulum stress and Akt with OSU-03012 and gefitinib or erlotinib to overcome resistance to epidermal growth factor receptor inhibitors.
Journal: Cancer research 20080415
Title: OSU-03012 stimulates PKR-like endoplasmic reticulum-dependent increases in 70-kDa heat shock protein expression, attenuating its lethal actions in transformed cells.
Journal: Molecular pharmacology 20080401
Title: Sensitizing estrogen receptor-negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor.
Journal: Molecular cancer therapeutics 20080401
Title: Cyclooxygenase-2 independent effects of cyclooxygenase-2 inhibitors on oxidative stress and intracellular glutathione content in normal and malignant human B-cells.
Journal: Cancer immunology, immunotherapy : CII 20080301
Title: Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs.
Journal: Expert opinion on investigational drugs 20080201
Title: 2-amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl} acetamide (OSU-03012), a celecoxib derivative, directly targets p21-activated kinase.
Journal: Molecular pharmacology 20071101
Title: PDK-1/AKT pathway as a novel therapeutic target in rhabdomyosarcoma cells using OSU-03012 compound.
Journal: British journal of cancer 20070911
Title: The phosphoinositide-dependent kinase-1 inhibitor 2-amino-N-[4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-acetamide (OSU-03012) prevents Y-box binding protein-1 from inducing epidermal growth factor receptor.
Journal: Molecular pharmacology 20070901
Title: OSU-03012, a novel celecoxib derivative, is cytotoxic to myeloma cells and acts through multiple mechanisms.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20070815
Title: Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
Journal: Molecular pharmacology 20061101
Title: OSU-03012 promotes caspase-independent but PERK-, cathepsin B-, BID-, and AIF-dependent killing of transformed cells.
Journal: Molecular pharmacology 20060801
Title: A structurally optimized celecoxib derivative inhibits human pancreatic cancer cell growth.
Journal: Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 20060201
Title: Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance.
Journal: Blood 20050515
Title: A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary CLL cells and transformed B-cell lymphoma cell line via a caspase- and Bcl-2-independent mechanism.
Journal: Blood 20050315
Title: From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors.
Journal: Cancer research 20040615
Title: Structure, regulation and function of PKB/AKT--a major therapeutic target.
Journal: Biochimica et biophysica acta 20040311
Title: Role of Akt signaling in vascular homeostasis and angiogenesis.
Journal: Circulation research 20020628
